{"id":533343,"date":"2021-03-09T11:54:01","date_gmt":"2021-03-09T11:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=533343"},"modified":"2021-03-09T11:54:01","modified_gmt":"2021-03-09T11:54:01","slug":"sickle-cell-disease-pipeline-analysis-unmet-needs-opportunities-key-players-sanofi-pfizer-bristol-myers-squibb-gilead-sciences-novo-nordisk-and-many-more","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sickle-cell-disease-pipeline-analysis-unmet-needs-opportunities-key-players-sanofi-pfizer-bristol-myers-squibb-gilead-sciences-novo-nordisk-and-many-more_533343.html","title":{"rendered":"Sickle Cell Disease Pipeline Analysis, unmet needs, opportunities, Key Players: Sanofi, Pfizer, Bristol Myers Squibb, Gilead Sciences, Novo Nordisk and Many More"},"content":{"rendered":"
\"Sickle<\/a><\/p>\n
\n
Sickle Cell Disease Pipeline<\/div>\n<\/div>\n<\/div>\n

“Sickle Cell Disease Pipeline Insight, 2021” <\/strong>report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Sickle cell disease pipeline landscape.<\/strong><\/p>\n

The assessment part of the report embraces in-depth Sickle Cell Disease commercial assessment<\/strong> <\/strong>and clinical assessment of the Sickle Cell Disease pipeline products from the pre-clinical developmental phase to the marketed phase. <\/p>\n

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sickle Cell Disease collaborations<\/strong>, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

 <\/p>\n

Sickle Cell Disease market<\/a> size<\/em><\/strong> is expected to increase during the forecast period owing to the launch of upcoming therapies.<\/em><\/strong><\/p>\n

 <\/p>\n

Sickle Cell Disease Companies<\/strong>:<\/strong><\/p>\n

• CSL Behring<\/p>\n

• Magenta Therapeutics<\/p>\n

• Molecules for Health<\/p>\n

• Hillhurst Biopharmaceuticals<\/p>\n

• ORYZON therapeutics<\/p>\n

• Regenacy Pharmaceuticals<\/p>\n

• Dystrogen Therapeutics<\/p>\n

• ReveraGen<\/p>\n

• Editas Medicine<\/p>\n

• Bioverativ ( A Sanofi company)<\/p>\n

• Genethon<\/p>\n

• Syros Therapeutics<\/p>\n

• Gilead Sciences<\/p>\n

• Bluebird bio<\/p>\n

• CRISPR Therapeutics<\/p>\n

• Novo Nordisk<\/p>\n

• Forma Therapeutics<\/p>\n

• La Jolla<\/p>\n

• Merganser Biotech<\/p>\n

• NuvOx Pharma<\/p>\n

• Pfizer<\/p>\n

• Sanofi<\/p>\n

• LEO Pharma<\/p>\n

• Invenux<\/p>\n

• Micelle BioPharma<\/p>\n

• AstraZeneca<\/p>\n

• Merck Sharp & Dohme<\/p>\n

• Angiocrine Bioscience<\/p>\n

• Beam Therapeutics<\/p>\n

• Fulcrum Therapeutics<\/p>\n

• Nicox<\/p>\n

• Shire<\/p>\n

• TauTona Group<\/p>\n

• EpiDestiny<\/p>\n

• RadioRx<\/p>\n

• Bellicum Pharmaceuticals<\/p>\n

• Novartis<\/p>\n

• Miltenyi Biotec<\/p>\n

• Nova Laboratories<\/p>\n

• Gamida-Cell<\/p>\n

• Addmedica Sasa<\/p>\n

• Bristol Myers Squibb<\/p>\n

• Imara<\/p>\n

• Ironwood<\/p>\n

• ARUVANT (Roivant’s Vant)<\/p>\n

• Prolong Pharmaceuticals<\/p>\n

• Modus Therapeutics<\/p>\n

 <\/p>\n

Request for free sample report: https:\/\/www.delveinsight.com\/sample-request\/sickle-cell-disease-pipeline-insight<\/a><\/strong><\/p>\n

 <\/p>\n

Sickle Cell Disease Therapies<\/strong> Covered in the Report Include:<\/strong><\/p>\n